---
title: "CSPC PHARMA's subsidiary sells core business for 230 million RMB"
description: "CSPC PHARMA announced that its subsidiary, CSPC Innovation, will sell its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full media communication business platform, fo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277049202.md"
published_at: "2026-02-26T13:28:46.000Z"
---

# CSPC PHARMA's subsidiary sells core business for 230 million RMB

> CSPC PHARMA announced that its subsidiary, CSPC Innovation, will sell its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full media communication business platform, for a cash consideration of 230 million RMB. The estimated loss from the sale is approximately 15 million RMB

CSPC PHARMA (01093.HK) announced that its subsidiary, CSPC Innovation, is selling its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full-media communication business platform, for a cash consideration of 230 million RMB. The estimated loss from the sale is approximately 15 million RMB

### Related Stocks

- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [562050.CN - Hwabao WP CSI Pharmaceuticals ETF](https://longbridge.com/en/quote/562050.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 上海复星医药旗下子公司在中国获得肺癌药物的试验许可 | 上海复星医药子公司获得中国肺癌药物临床试验批准 | [Link](https://longbridge.com/en/news/276886600.md) |
| 百济神州 Q4 营收同比增长 33%，全年扭亏为盈，百悦泽单季狂揽 11 亿创历史新高｜财报见闻 | 百济神州 2025 年全年营收 53.43 亿美元，同比增长 40%。旗舰药百悦泽全球销售额达 39 亿美元，稳居赛道第一。公司经营现金流与净利润双双转正，彻底告别 “烧钱” 模式。展望 2026 年，随新药临近商业化，总收入指引上调至 6 | [Link](https://longbridge.com/en/news/277044073.md) |
| 上海医药获得新加坡市场批准用于抗凝药物 | 上海医药获得新加坡抗凝药物的市场批准 | [Link](https://longbridge.com/en/news/276822785.md) |
| 中国的九源基因正在寻求 Wegovy 生物类似药的批准 | 九源基因生物医药已申请在中国销售其 Wegovy 的生物仿制药版本，正值关键专利到期之前。该公司报告称，其三期临床试验显示，吉可沁在安全性和减重效果上与 Wegovy 具有临床等效性。九源还在寻求 Ozempic 的生物仿制药版本的批准，旨 | [Link](https://longbridge.com/en/news/276994337.md) |
| 杭州久远的司美格鲁肽生物类似药吉克勤正在推进中国市场的审批 | 杭州久远基因工程有限公司开发了 Jikeqin，这是一种用于体重管理的赛马鲁肽生物仿制药。该药物在三期临床研究中显示出临床等效性，中国国家药品监督管理局已接受其上市申请。这标志着在肥胖治疗市场商业化的重要一步。该公司专注于代谢疾病的创新疗法 | [Link](https://longbridge.com/en/news/276936312.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.